Ms. Yardeni joins the Company from Teva Pharmaceutical Industries, where she worked for the past 17 years, most recently as VP, Head of Global Clinical Operation, Global R&D.
From 1999 to 2011, she held positions of increasing responsibility in the area of Biometrics at Teva, including six years of managing the Global Data Management Center of Excellence.
Previously Ms. Yardeni served as a Statistician at Technostat, a Clinical Research Organization.
She received both her B.A. in Statistics and M.A. in Applied Statistics from Haifa University.
Mr. Shor has 18 years of experience in the development, registration, production and commercialization of medical devices, most recently as Chief Executive Officer of PerfAction Technologies. In this capacity he led the company from the R&D stage to global commercialization.
From 2009 to 2013, Mr. Shor was COO of PerfAction Technologies, where he led multi-disciplinary R&D teams that integrated mechanics, electronics, pneumatics, and software development.
From 2003 to 2009, he held positions of increasing responsibility at GI View. These positions included Mechanical & System Manager, VP of R&D & COO.
Previously Mr. Shor held positions in Mechanical Engineering at Nova and Elan Medical, where he took part in developing a wearable drug delivery pump.
He received his B.Sc. in Mechanical Engineering from Tel Aviv University. ■
LATEST MOVES FROM Israel
- Teva appoints Kåre Schultz as CEO
- Immune Pharma appoints Tony Fiorino as COO
- Enzymotec appoints Dror Israel as CFO
- Intec Pharma appoints Jeffrey A. Meckler as CEO
- Foamix Pharmaceuticals names David Domzalski as CEO
More inside POST